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Hepatocellular carcinoma (HCC) is the most common primary malignant tumor 
of the liver in adults. Steatohepatitic HCC (SH-HCC) is a recently described, rarer 
variant of HCC and is associated with nonalcoholic fatty liver disease (NAFLD). 
The relationship between fatty liver disease and/or steatohepatitis and SH-HCC 
is now known. This subtype can be confused with lipid-containing nodules (such 
as cirrhotic nodules, regenerative nodules, focal nodular hyperplasia) clinically, 
radiologically and histopathologically. Here, the histopathological features of 
SH-HCC, its relationship with fatty liver disease and briefly its clinical features will 
be discussed. In addition, histopathological features of this specific variant, immu-
nohistochemical staining of the tumor and diagnostic difficulties in tru-cut biopsies 
will also be discussed. Actually, I think this article will raise clinicopathological 
awareness about this rare variant.
Keywords: Hepatocellular carcinoma, steatohepatitic HCC, steatohepatitis, NASH, 
alcoholic steatohepatitis, IHC
1. Intoduction
Hepatocellular carcinoma (HCC) is the most common primary malignant tumor 
of the liver in adults, the fifth most common cancer in the world and also the third 
most common cancer of cancer-related deaths [1]. It is the malignancy of hepato-
cytes with varying degrees of differentiation [2]. The most common cause of death 
in patients with HCC is cirrhosis. Despite all the unknowns, heptocarcinogenesis is 
a multistep process, and chronic inflammation plays the major role [2–6].
2. Epidemiology and etiology
HCC has a multifactorial etiology, and its incidence and prevalence varies 
by country [7]. Although the incidence of HCC is different in different geogra-
phies, the incidence increases with age [8]. It is more common in men than in 
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women (male:female ratio; ranging between 2:1 and 4:1 in various countries). 
Cirrhosis, viral hepatitis, alcohol, aflatoxin, metabolic diseases, metabolic 
syndrome characterized by fatty liver are the main causes of HCC etiology. 
Although the activation of the WNT/B-catenin pathway is one of the main 
events in HCC, the effects of viral antigens on the nucleus, mutations, and DNA 
instability constitute the pathogenesis of HCC [9]. There are also molecular 
studies showing that activation of the JAK/STAT pathway also contributes to the 
development of SH-HCC [1, 10].
2.1 Cirrhosis
Most patients with HCC have underlying liver cirrhosis. Cirrhosis is therefore 
considered a major risk factor for HCC [8, 11, 12]. Although macronodular cirrhosis 
is considered as a higher risk for HCC than micronodular cirrhosis, cirrhotic liver 
can create HCC for any reason [13]. Cirrhosis also has a geographical distribution, 
the etiology of cirrhosis is chronic viral hepatitis in Asian countries, and nonviral 
causes in European and American countries [14]. Despite this known association 
between cirrhosis and HCC, HCC also develops from the noncirrhotic liver [15–17].
2.2 Viral hepatitis (hepatitis B and hepatitis C)
Most HCCs develop from the background of chronic viral hepatitis, including 
hepatitis B and Hepatitis C [18–21]. Viral hepatitis-related HCCs are more common 
in countries where hepatitis B and hepatitis C are more prevalent, such as Asia 
and Africa. Viral-related HCC appears to be decreasing in countries where clinical 
follow-up increases, and whom include hepatitis B vaccine in regular vaccination 
programme. Integration of hepatitis B virus into the host hepatocyte genome is 
thought to initiate hepatocarcinogenesis. In the etiology of HCC, hepatitis C is as 
important as hepatitis B [22–24]. Being men and older, having coinfection (such 
as HBV, HIV), alcohol use, diabetes, and fatty liver constitute a high risk for HCC 
formation. Even the development of HCC in liver coinfected with hepatitis C and 
hepatitis B viruses, is higher than in those infected with other viruses [13]. It is 
thought that ongoing liver damage and accompanying regeneration caused by 
the immune response and direct cytopathic effect in hepatitis C infection induce 
malignant transformation [25, 26].
2.3 Aflatoxin
Consumption of foods contaminated with aflatoxins produced by fungi can lead 
to the formation of HCC [8, 27, 28]. Aflatoxin B1, one of the toxin types, is thought 
to be mainly responsible for HCC formation [8]. It contributes to the formation of 
HCC by making mutations (Guanin and Thymine mutations) in DNA via cyto-
chrome p450. Aflatoxin exposure is thought to affect patients with chronic HCV 
hepatitis more [8, 29, 30].
2.4 Alcohol
The relationship between alcohol use and HCC is both by direct effect and being 
a cofactor in viral infections [31, 32]. Reactive oxygen radicals, that occur while 
alcohol is metabolized to acetaldehyde, initiate hepatocarcinogenesis by causing 
damage and transformation in DNA. HCC development in alcoholic cirrhosis is in 
the form of DNA instability caused by DNA hypomethylation [33–36].
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2.5 Metabolic diseases
HCC can develop in some of the livers with metabolic diseases. However, the 
development of HCC is more common with hereditary hemochromatosis, tyro-
sinemia and α1-antiripsin deficiency [37–41]. In these diseases, the direct toxic 
effect of accumulations (such as iron), mutation (p53 mutation), immunological 
abnormalities and DNA damage by lipid peroxidation initiate the development of 
HCC [8, 42, 43].
2.6 Metabolic syndrome and fatty liver disease
Metabolic syndrome is a mortal endocrinopathy that is accompanied by systemic 
disorders such as abdominal obesity that begins with insulin resistance, diabetes, 
dyslipidemia, hypertension and coronary artery disease. This situation has led to 
an increase in HCC formation, which has the characteristics of metabolic syndrome 
[44–47]. The risk of HCC increases 2–3 times in patients with diabetes [37, 48, 49]. 
The increase in metabolic syndrome in developed countries also brought an increase 
in nonalcholic fatty liver disease (NAFLD) [50–55].
In obese patients, the decrease in the release of fatty acids from adipose tissue, 
tumor necrosis factor-α and adiponectin causes insulin resistance and thus chronic 
hyperinsulinemia. Insulin and insulin growth factor-1 (IGF-1) contribute to hepa-
tocarcinogenesis by preventing apoptosis and increasing cellular proliferation with 
the signals they send to insulin receptors and IGF-1 receptors [8].
Since steatohepatitic HCC (SH-HCC) will be mentioned here, NAFLD, steato-
hepatitis and their associated HCC formation mechanism are explained in a little 
more detail.
There are many studies on the incidence and prevalence of HCC in NAFLD cases, 
with rates varying between 3 and 35% [51, 56, 57]. Steatohepatitis varies between 3 
and 5%. In some cohort studies, the rate of development of HCC (1-year cumulative 
incidence) was reported as 2–5% in patients with NAFLD compared to hepatitis 
C cases. The 5-year incidence was reported as 11% [51, 58]. In another study, the 
annual cumulative rate was 2–6%. In a retrospective study, NAFLD was detected in 
21.2% of HCC cases. In fact, 23% of NAFLD patients without histopathologically 
and radiologically significant cirrhosis developed HCC [59]. In a different study, 
HCC develops in 5% of patients with cirrhosis secondary to NAFLD [53]. In cohort 
studies with large case series, both steatosis and steatohepatitis in nontumoral liver 
were found to be statistically significant with HCC. Moreover, a close relationship 
between the steatohepatitic variant of HCC (SH-HCC), which has been recently 
defined, and NAFLD has been described and demonstrated [22, 53, 58, 60]. 
Although its relationship with fatty liver diseases has been clarified, there are studies 
showing that SH-HCC can also develop in viral hepatitis [16, 61].
3. Clinical features
The clinical manifestations of HCC are quite ambiguous and are related to 
the tumor and underlying chronic liver disease [1]. Usually, patients show signs 
in advanced stages and even miss the chance of treatment. Patients may present 
with upper abdominal pain, hepatomegaly, splenomegaly, weight loss, jaundice or 
decompensated liver finding such as ascites [1, 8]. HCC most commonly spreads 
intrahepaticly via the portal vein [1]. While HCC spreads with intrahepatic portal 
vein branches, the main portal vein and hepatic vein involvement can also be seen. 
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Invasion of the bile duct causes liver decompensation, resulting in rapid ascites 
accumulation, obstructive jaundice, variceal hemorrhages, and hepatic encepha-
lopathy [8]. Although extrahepatic dissemination is rare, it can metastasize to the 
lung, lymph nodes, bone, and adrenal gland in advanced disease [1]. Paraneoplastic 
syndrome findings such as hypoglycemia, hypercholesterolemia, hyperkalemia, 
gynecomastia, carcinoid syndrome, hypertrophic pulmonary osteoarthropathy, 
osteopetrosis, hypertension, hyperthyroidism, porphyria cutanea tarda can be seen 
[8]. Median suvival in patients with clinical findings who have the chance for cura-
tive treatment is around 1–3 months, and survival over 1 year is also unusual. Today, 
thanks to definitive treatments and advanced surgeries, patients at risk of develop-
ing HCC are followed more closely and the tumor is diagnosed at an early stage [8, 
28]. Radiologic imaging methods (ultrasound, computed tomography, magnetic 
resonance imaging, angiography) are used for the diagnosis of liver masses and 
HCC [8, 17, 62, 63].
4. Pathological features
HCC is a highly heterogeneous tumor. Heterogeneity is both molecular and mor-
phological [64, 65]. Understanding the heterogeneity is important for the diagnosis, 
treatment and follow-up of the disease [64].
HCCs below 2 cm are called small HCC (s-HCC) and early HCC (e-HCC)  
[1, 64, 66]. These tumors are divided into two as prominent nodular or indistinct 
nodules [64]. Early-HCC is in the form of nodules with indistinct borders and 
usually develops from a dysplastic nodule background. They are well differenti-
ated, develop from the background of fibrosis-cirrhosis, and are radiologically 
hypovascular and rarely vascular invasion (5%) [1, 64]. Small-HCC has a promi-
nent pseudocapsule, is well-moderately differentiated, radiologically hyper-
vascular, and invades more frequently (40%) [1, 64]. Pedinculated HCC has a 
growth pattern protruding from the capsular surface [67]. Diffuse HCC is in the 
form of proliferation of small tumor nodules and resembles cirrhotic nodules 
(cirrhotomimetic) [64]. SH-HCC is more solid than other HCC subtypes and 
has more golden-yellow color due to the lipid contains. When the macroscopic 
specimen is carefully examined, fibrotic bands that divide the tumor into lobules 
can be seen. The tumor usually tends to be well-circumscribed or nodular and 
may range in diameter from 0.5 cm to 11 cm [68]. The prognosis of SH-HCC is 
similar to that of classical HCC [40, 57, 69, 70]. Although nontumoral liver can 
be cirrhotic or noncirrhotic, it is usually yellowish-brown in color suggestive of 
fatty liver (Figure 1).
After these macroscopic definitions and macroscopic heterogeneity, it is neces-
sary to mention microscopic heterogeneity. This heterogeneity is also reflected in the 
histopathological subtyping of HCC [71]. In the 5th edition of WHO classification 
of the tumors of the digestive system (2019), the subtypes of HCC are as follows; 
fibrolamellar, scirrhus, cear cell type, steatohepatitic, macrotrabecular massive, chro-
mophobe, neutrophil-rich, lympocyte-rich [1]. More on SH-HCC will be mentioned 
here. SH-HCC is a newly identified subtype of HCC. It accounts for approximately 
5–20% of all HCCs [1]. It is characterized by steatohepatitic features such as steato-
sis in tumor cells, balloon degeneration, inflammation, Mallory-Denk bodies and 
pericellular fibrosis [58, 72]. Tumor is usually related to MetS and steatohepatitis is 
detected in the background. [22, 39, 57, 61, 69, 72]. Some studies have shown  
that steatosis and interstitial fibrosis are the main findings for SH-HCC [22, 40].  
However, the minimum amount of steatosis in the steatohepatitic area in some tumors 
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that are histomorphologically SH-HCC, the presence of only steatosis in some cases, 
the presence of steatotic areas or cells in HCC are confusing points in the diagnosis of 
SH-HCC. Despite all this confusion, the steatohepatitic area in HCC is diagnostic for 
SH-HCC. For the histopathological diagnosis of SH-HCC, the cut-off for steatohepa-
titic features was described more than 5% of the tumor before but later moved to 50% 
[10, 39, 64, 72]. Hepatocellular carcinoma morphologically has 4 histological growth 
patterns: trabecular, solid (compact), pseudoaglandular (pseudoacinar), and macro-
trabecular (trabecular thickness consisting of more than 10 cells) [1]. When SH-HCC 
is examined microscopically, a steatotic tumor is seen, separated from the generally 
steatotic liver (cirrhotic or non-cirrhotic) by a nodular or infiltrative margin. Large 
fat droplets are detected in tumor cells. Mallory-Denk bodies are detected in most 
tumors. Thin connective tissue growth (pericellular fibrosis), trabecular fibrosis, 
and randomly distributed collagen bundles surrounding tumor cells can be easily 
selected. Trabecular fibrosis, including randomly distributed collagen bundles in the 
tumor, and fibrosis surrounding tumor cells (pericellular) can be easily distinguished. 
Inflammation in the tumor is also remarkable. The inflammation is lymphocyte 
predominant with sparse plasma cells. More prominent neutrophil and lymphocyte 
infiltrations can be detected around tumor cells which contains Mallory-Denk bodies. 
The nuclei of tumor cells have atypia. This atypia is mild in well-differentiated tumors 
and quite pronounced in poorly differentiated tumors. They may even have bizarre 
nuclei suggested of sarcomas or pleomorphic carcinomas. However, mitotic activity 
is very low. Again, as in classical HCC and other subtypes, the tumor does not contain 
portal tracts and unpaired arteries can be seen (Figures 2–4) [1, 10, 45, 68, 72, 73]. 
The differentiation of SH-HCC is the same as that of classical HCC and is graded as 
well differentiated (Grade1: Tumor cells resemble mature hepatocytes with minimal 
to mild atypia), moderately differentiated (Grade 2: Distinctly malignant and histo-
morphology strongly suggests hepatocellolar differentiation) and poorly differenti-
ated (Grade 3: Clearly malignant, but histomorphology strongly suggests spectrum of 
Figure 1. 
Tumor with nodular border is seen in the brown-yellow noncirrhotic liver. The tumor is lobulated by fibrotic 
bands and has yellow areas.
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poorly differentiated carcinomas) [1]. Most SH-HCCs are moderately differentiated 
and have a trabecular pattern and a pseudoglandular pattern [52].
Immunohistochemical antibodies are helpful and supportive in the diagnosis 
of HCC [74]. Although heppar-1, glypican-3, glutamine synthetase, arginase, 
heat shock protein-70 (HSP-70), β-catenin and sinusoidal staining with CD34, 
Figure 2. 
The tumor (pale area) is located in the center of the figure, surrounded by cirrhotic nodules (a, Hematoxylin 
and Eosin-H&E). Masson’s trichrome (b) and reticulin (c) stains, both the tumor and its surrounding 
micronodular cirrhotic background are more prominent.
Figure 3. 
The parenchymal invasion area of steatohepatitic HCC is seen (arrows) (a), the tumor is seen adjacent to the 
fatty cirrhotic nodule (stars) (b), presence of large lipid droplets and chronic inflammation (arrows) (c), 
Masson’s trichrome stain shows thick fibrous septa (arrows) (d).
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canalicular staining pattern with polyclonal carcinoma embryogenic antigen 
(pCEA) and CD10 antibodies are used in the diagnosis of HCC, immune studies for 
SH-HCC are limited (Figure 5) [22, 68, 72, 75].
Figure 4. 
Dense inflammation and fibrosis (a), pleomorphism (b), Mallory-Denk bodies (arrows) (c), and ballooning 
(cells with pale cytoplasm) (d) are seen in different areas of the tumor.
Figure 5. 
Glutamine synthetase shows positive cytoplasmic staining (a), CD10 antibody shows positive canalicular 
staining (b).
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The histopathological diagnosis of SH-HCC is usually easy in cases with explant 
and resection. However, tru-cut biopsies, which represent a small part of the tumor, 
may have diagnostic difficulties. These diagnostic difficulties are due to both the 
heterogeneity of the tumor and its similar morphological appearance to NAFLD 
with advanced fibrosis. A tru-cut biopsy from focal nodular hyperplasia (FNH) 
with fatty changes sometimes can be confused with a diagnosis of nodular and 
well differentiated SH-HCC. This difference between the diagnosis in the tru-cut 
biopsy and the resection material should not be interpreted as a misdiagnosis. 
Before interpreting it as an erroneous diagnosis, it should be remembered that 
this diagnostic difference is due to the heterogeneous and fat-containing nature of 
the tumor. Pathologists should remember that bile duct proliferation, presence of 
central scar (histologically and radiologically), and thick-walled abnormal vascular 
structures in the fibrous septa are more common in FNH when examining this tru-
cut biopsy. Since fibrosis can be seen in both SH-HCC and FNH, it may not clarify 
the differential diagnosis. Non-invasive border and immunohistochemical staining 
(sinusoidal CD34 staining, glypican-3 positivity and diffuse glutamine synthetase 
staining) may be helpful in the differential diagnosis of steatohepatitis [8, 11, 68, 
72]. Differentiation from classical HCC can be made by evaluating morphological 
and immune markers together [68]. In spite of all this, it would be appropriate to 
consult a pathologist experienced in liver pathology in cases where tumor specifica-
tion could not be made.
The relationship between NAFLD, NASH, and HCC (especially SH-HCC) is 
now known. Adequate tumor sampling should be performed in resection materi-
als, explants, particularly when identifying subtypes of large-diameter HCCs. It 
should be noted that classical HCC and other subtypes, including SH-HCC, have a 
heterogeneous histomorphology. While patients with metabolic syndrome, insulin 
resistance, obesity, fatty liver and steatohepatitis are followed up, careful radio-
logical examination should be performed for SH-HCC that may develop from this 
background. In other words, the terminology of “neoplastic steatogenesis” should 
be kept in mind.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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